secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-284579
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics Q3 net loss narrows to $11.7M; secures $75M from GSK license and equity investment
--------------------------------------------------------------------------------

- Net loss $11.7M ($0.33/shr) vs $22.5M ($0.70/shr) in Q3 2021; revenue $2M down from $3.1M.
- Cash $50.4M at Sep 30; post-Q3 received $9M GSK equity, $66M upfront invoiced; runway extended beyond 2024.
- GSK license for tebipenem HBr closed; $66M upfront, $9M equity, up to $525M milestones plus tiered royalties.
- SPR720 Phase 2 trial initiated for NTM pulmonary disease; top line data expected 1H 2024.
- Kamal Hamed joined as CMO in Sep 2022; received inducement awards of 210k RSUs and 140k PSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/0001193125-22-284579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/d189186d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-284579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer